Keywords
Abstract
The study evaluated the effectiveness of intravesical prednisolone in 40 patients with chronic cystitis complicated by bladder ulceration. Patients were divided into three groups: standard therapy, prednisolone monotherapy, and combined treatment with antibiotics plus prednisolone. Prednisolone led to greater ulcer reduction, improved symptoms, and better inflammatory markers compared with standard therapy, while the combined regimen produced the strongest overall clinical response. Intravesical prednisolone was well tolerated and showed no systemic adverse effects. The findings support its use as an effective component in the management of ulcerative chronic cystitis.
References
Akiyama Y., Niimi A., Nomiya A., et al. Efficacy and Safety of Low-Dose Prednisolone in Refractory Hunner-Type Interstitial Cystitis // European Urology Open Science. — 2023. — Vol. 56. — P. 1–8.
Yu W.-R., Wang X.-M., Liu J.-N. Chronic Bladder Inflammation: Mechanisms and Current Treatment Strategies // Biomolecules. — 2024. — Vol. 12, № 9. — P. 2051–2065.
Sweeney T., Nguyen L. Intravesical Therapy in Bladder Pain Syndrome: Current Evidence and Future Directions // Current Bladder Dysfunction Reports. — 2024. — № 19. — P. 112–124.
Jeong H.J., Shim M.S., Roh J.-L. Effects of a Short Course of Prednisolone in Bladder Pain Syndrome // International Neurourology Journal. — 2012. — Vol. 16, № 4. — P. 175–180.